SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+1.68%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.06B
AUM Growth
+$1.06B
(+7.7%)
Cap. Flow
+$109M
Cap. Flow
% of AUM
10.32%
Top 10 Holdings %
Top 10 Hldgs %
61.71%
Holding
84
New
16
Increased
22
Reduced
6
Closed
13
Top Buys
| 1 |
NextCure
NXTC
|
$37.8M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$34.6M |
| 3 |
PTC Therapeutics
PTCT
|
$16.6M |
| 4 |
Ascendis Pharma
ASND
|
$11.7M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$9.9M |
Top Sells
| 1 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$17.1M |
| 2 |
AstraZeneca
AZN
|
$10.6M |
| 3 |
AnaptysBio
ANAB
|
$7.16M |
| 4 |
Xencor
XNCR
|
$6.52M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$6.43M |
Sector Composition
| 1 | Healthcare | 91.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $127M | 11.64% | 1,099,824 +101,286 | +10% | +$11.7M |
|
|
AMRN
2
Amarin Corp
AMRN
$311M
| $101M | 9.28% | 5,208,305 | – | – |
|
3
Natera
NTRA
$23.1B
| $85.5M | 7.86% | 3,100,560 | – | – |
|
|
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $67.6M | 6.22% | 2,038,208 | – | – |
|
|
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $53.7M | 4.94% | 4,749,623 | – | – |
|
|
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $49.3M | 4.53% | 481,270 | – | – |
|
7
Y-mAbs Therapeutics
YMAB
$388M
| $48.1M | 4.42% | 2,104,278 | – | – |
|
|
8
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $46.3M | 4.25% | 2,093,221 -775,000 | -27% | -$17.1M |
|
|
9
NextCure
NXTC
$13.5M
| $37.8M | 3.47% | +2,521,856 | New | +$37.8M |
|
|
BOLD
10
DELISTED
Audentes Therapeutics, Inc
BOLD
| $35.3M | 3.25% | 933,640 | – | – |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $34.6M | 3.18% | +1,729,352 | New | +$34.6M |
|
12
Merus
MRUS
$4.98B
| $28.7M | 2.64% | 1,961,039 | – | – |
|
|
NCNA
13
NuCana
NCNA
$6.09M
| $23.5M | 2.16% | 2,266,666 | – | – |
|
|
14
PTC Therapeutics
PTCT
$3.92B
| $16.6M | 1.53% | +368,903 | New | +$16.6M |
|
15
Novo Nordisk
NVO
$251B
| $16.5M | 1.52% | 323,697 +75,963 | +31% | +$3.88M |
|
|
AGN
16
DELISTED
Allergan plc
AGN
| $14.1M | 1.3% | 84,433 -4,232 | -5% | -$709K |
|
17
Neurocrine Biosciences
NBIX
$13.8B
| $13.2M | 1.21% | 155,860 +43,454 | +39% | +$3.67M |
|
18
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $12.5M | 1.15% | 922,700 | – | – |
|
|
CHMA
19
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $12.2M | 1.12% | 1,630,221 | – | – |
|
20
Iterum Therapeutics
ITRM
$30.2M
| $11.9M | 1.09% | 1,726,514 | – | – |
|
21
Halozyme
HALO
$8.56B
| $11.9M | 1.09% | 690,199 +288,870 | +72% | +$4.96M |
|
22
Heron Therapeutics
HRTX
$207M
| $11.5M | 1.05% | 617,185 +383,534 | +164% | +$7.13M |
|
23
TG Therapeutics
TGTX
$4.65B
| $10.9M | 1% | 1,261,384 +909,573 | +259% | +$7.87M |
|
|
RETA
24
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $10.9M | 1% | 115,536 +50,505 | +78% | +$4.77M |
|
|
XLRN
25
DELISTED
Acceleron Pharma Inc.
XLRN
| $9.9M | 0.91% | +241,043 | New | +$9.9M |
|